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Purinergic signaling in bone was ﬁrst proposed in the early 1990s with the observation that
extracellular ATP could modulate events crucial to the normal functioning of bone cells.
Since then the expression of nearly all the P2Y and P2X receptors by osteoblasts and
osteoclasts has been reported, mediating multiple processes including cell proliferation,
differentiation, function, and death.This reviewwill highlight themost recent developments
in the ﬁeld of purinergic signaling in bone, with a special emphasis on recent work resulting
from the European Framework 7 funded collaboration ATPBone, as well as Arthritis
Research UK and Bone Research Society supported projects.
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INTRODUCTION
Purinergic signaling is the most primitive and ubiquitous cell-
to-cell signaling system that exists (Burnstock and Verkhratsky,
2012a). It involves the energy molecule adenosine triphosphate
(ATP) and its breakdown products being used outside of the cell
to bind speciﬁc receptors called purinoceptors which then direct
the action and fate of cells. Just as every living organism uses
ATP for energy, nearly every cell will express purinoceptors and
use purinergic signaling to control cellular functions (for a recent
review, see Burnstock and Verkhratsky, 2012b).
In the context of bone, purines and pyrimidines are present in
the extracellular milieu, either as a consequence of lytic or con-
trolled release. Upon binding speciﬁc cell surface purinoceptors
expressed by the different cell types in bone, intracellular cal-
cium signaling cascades are triggered to direct the fate of bone
cells and ultimately control bone homeostasis. Regulation of
purinergic signaling in bone involves the co-ordinated actions
of (1) controlled release of purines and pyrimidines from bone
cells; (2) the expression and activity of enzymes on the surface
of bone cells that can breakdown or interconvert ATP and other
nucleotides; (3) purinoceptor expression by bone cells which is
tightly controlled in a temporal and spatial manner.
Purinergic signaling in bone was ﬁrst proposed in the early
1990s with the observation that extracellular ATP could raise
intracellular calciumand induce secondarymessenger activation –
events crucial to the normal functioning of osteoblasts (Kumagai
et al., 1991; Schoﬂ et al., 1992). Since then it has been reported
that osteoblasts and osteoclasts (of one species/type or another)
express nearly all of the P2Y and P2X receptors, mediating mul-
tiple cellular processes and providing a mechanism to integrate
local (i.e., ATP) and systemic (i.e., PTH) signaling to control
bone turnover. For an extensive historical reviews of puriner-
gic signaling in bone, see Grol et al. (2009), Orriss et al. (2010),
Reyes et al. (2011), Gartland (2012), Gartland et al. (2012a), and
Bowler et al. (2001).
This review will discuss the most recent developments in the
ﬁeld of purinergic signaling in bone, highlighting work from a
recent European Framework 7 funded collaboration called ATP-
Bone, as well as Arthritis Research UK and Bone Research Society
funded projects (see Figure 1 for a summary).
MODULATION OF ATP RELEASE FROM BONE CELLS
Bone is subjected to awide array of mechanical stimuli that include
ﬂuid shear stress which occurs when the interstitial ﬂuid within
the canaliculi of bone ﬂows past the cells of bone in response to
movement, substrate strain, and compressive loading (Ehrlich and
Lanyon, 2002; Baron, 2003; Klein-Nulend et al., 2005). It is well
established that mechanical stimulus applied to cells in vitro, even
as subtle as ﬂuid movements after a medium change, can increase
basal ATP release (Lazarowski et al., 2000). A role for ATP release
in the process of mechanotransduction in bone has been suggested
for some time now (Turner, 2006), although, as with the original
concept of purinergic signaling, it is not yet widely acknowledged
or appreciated.
Progress in unraveling the processes behind ATP release
from osteoblasts has been advanced with results from a recent
study comparing the effects of all of the loading forms expe-
rienced by bone including ﬂuid ﬂow, ﬂuid shear stress, sub-
strate strain, and 3D compressive loading (Rumney et al., 2012).
ATP release was demonstrated to increase rapidly in response
to turbulent ﬂuid ﬂow, with a gradual increase in response
to ﬂuid shear stress and substrate strain. A functional conse-
quence of mechanical load-induced ATP release was shown to
be the activation of the osteogenic immediate early gene c-fos,
which was demonstrated to be activated most in response to
3D ﬂuid ﬂow and substrate strain. The results of this study,
which was partly funded by a Bone Research Society Barbara
Mawer Travelling fellowship, demonstrated that the amount
of ATP released in response to mechanical loading varied in
a time, direction, and strain-dependent manner and that this
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FIGURE 1 | Summary of purinergic signaling in bone. P2Y and P2X
receptor subtypes are expressed by most bone cell types and are activated
by extracellular nucleotides present in the microenvironment. (1) ATP release
from osteoblasts and osteoclasts occurs both constitutively and as a
consequence of mechanical loading, with the concentration of ATP released
varying in a time, direction and strain dependent manner. The P2Y13 receptor
may represent a negative feedback loop regulating ATP release from
osteoblasts. (2) Once in the microenvironment, ATP and its breakdown
products can activate either P2Y or P2X receptors. P2X7 receptors on
osteoclasts precursors are activated by higher concentrations of ATP and are
involved in the fusion and multinucleation of osteoclasts: antagonism of P2X7
receptors (α-P2X7) prevents this process. Similarly antagonism of P2Y12
receptors (α-P2Y12) prevents fusion of osteoclasts as well as their maturation
and activity. (3) Activation of P2Y1 and P2Y6 receptors increases osteoclast
resorption whilst absence of P2Y13 receptors (P2Y13R−/−) reduces
osteoclast number and activity. (4) ATP and other nucleotides are potent
potentiates of systemic factors such as PTH – providing a mechanism to
induce activation of osteoblasts above a threshold attained by systemic
factors alone to facilitate focal remodeling as occurs in the case of adaptive
remodeling in response to loading or PTH treatment. (5) Activation of P2
receptors in bone cells by ATP provides a mechanism to translate the
mechanical stimuli engendered in bone into a biological signal. This signal can
then be propagated through the network of cells in bone, including osteocytes
which have also been shown to release ATP upon mechanical loading.
may represent a local mechanostat in bone that may inﬂuence
osteogenesis.
Until recently, research on ATP release from bone cells has
focused on osteoblasts, with a few reports on release of ATP from
osteocytes (Genetos et al., 2007). A recent report highlights the
importance of the voltage-sensitive calcium channel α2δ1 auxil-
iary subunit in regulating mechanically induced ATP release in
the osteocytic cell line MLO-Y4 (Thompson et al., 2011) offering
further insights into the mechanisms behind regulation of ATP
release in response to mechanical load.
Exciting new data has also emerged on the release of ATP from
osteoclasts. In an oral presentation at the 2011 joint meeting of
the Bone Research Society & the British Orthopaedic Research
Society, Rumney et al. (2011) demonstrated for the ﬁrst time that
primary human osteoclasts release ATP and that active osteoclasts
have an enhanced sensitivity to ﬂuid ﬂow. Until then little, if any-
thing, had been reported on whether osteoclasts were capable of
releasing ATP either constitutively or in response to mechanical
loading. The concept that osteoclasts may be directly involved
in sensing mechanical loading in bone via ATP release is fur-
ther supported by recent data from Brandao-Burch et al. (2012)
reported in this research topic. They provided evidence for the
involvement of the mechanosensitive P2X7 purinoceptor in the
release of ATP from murine osteoclasts. Taken together, these two
reports provide an intriguing new direction of research in bone
mechanotransduction.
RECENT ADVANCES RELATING P2X7 RECEPTOR ACTIVITY
AND OSTEOCLAST MULTINUCLEATION
The P2X7 receptor was originally discovered as the P2Z recep-
tor, sensitive to high levels of ATP and thought to function only
in the cytotoxic effect of extracellular ATP (Falzoni et al., 1995) –
earning the receptor the nickname “the suicide receptor”! Many
advances have been made in elucidating the role of this recep-
tor since this initial proposed function (which surely would have
evolved it to extinction if only involved in suicide?) including the
release of cytokines and more contentiously cell fusion (Lemaire
et al., 2011a). Both these proposed functions play key roles in bone
homeostasis and accordingly several labs have investigated the role
of the P2X7 receptor in bone cells, and more speciﬁcally in osteo-
clast fusion and multinucleation: in vitro blockade of the receptor
prevents fusion (Gartland et al., 2003a), whilst the P2X7RKOmice
maintain the ability to form multinucleated osteoclasts in vitro
and in vivo (Gartland et al., 2003b; Ke et al., 2003; for review see
Gartland, 2012).
Multinucleation of osteoclasts is similarly a contentious issue –
it probably still remains a debate as to whether multinucle-
ation occurs to increase the efﬁciency of resorption, possibly
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via increased transcriptional activity (Boissy et al., 2002), or not
(Piper et al., 1992; Lees et al., 2001). Regardless of the reason
for multinucleation of osteoclasts, the role of the P2X7 receptor
in this process has been strengthened recently. Using a num-
ber of different P2X7 receptor antagonists, Agrawal et al. (2010)
demonstrated that all but one compound decreased the forma-
tion and function of multinucleatedTRAP-positive osteoclasts in a
concentration-dependent manner. Whilst this study provides fur-
ther evidence for the involvement of the P2X7 receptor in fusion
of osteoclasts, it did not elucidate the mechanism by which P2X7
receptors are involved in fusion. This was however, addressed in
another study by Pellegatti et al. (2011) in which they proposed
that P2X7 receptors are absolutely required for fusion of osteo-
clasts due to P2X7 receptor-dependent release of ATP which is
then broken down to adenosine with the subsequent activation
of adenosine receptors resulting in cell fusion. The role of P2X7
receptor inATP release-driven cell fusionwas also demonstrated to
be critical for the induction of multinucleated macrophages by the
inﬂammatory cytokineGM-CSF (Lemaire et al., 2011b). Targeting
the P2X7 receptor in diseases with increased osteoclast multinu-
cleation, such as Paget’s disease, may provide new therapeutic
options.
MOUSE MODELS TO DETERMINE FUNCTIONAL
CONSEQUENCES OF PURINERGIC SIGNALING IN BONE
Since the ﬁrst report over 20 years ago that extracellular ATP could
modulate intracellular calcium and second messenger signals in
bone (Kumagai et al., 1991; Schoﬂ et al., 1992) numerous groups
have reported the expression of P2X and P2Y subtypes by the
different bone cell types in a variety of species with wide rang-
ing functional consequences (see reviews listed above for speciﬁc
details). The most recent data to add to the catalog of expression
and function proﬁles has emerged following the bone phenotype
analysis of KO mice for P2Y6 receptor and the relatively recently
discovered P2Y13 receptor.
As part of the EU Framework 7 funded project “ATPBone:
Fighting osteoporosis by blocking nucleotides: purinergic signal-
ing in bone formation and homeostasis,” the P2Y6 and P2Y13
receptor KO mice (P2Y6R−/− and P2Y13R−/−) were made avail-
able by Bernard Robaye and Jean Marie Boeynaems from the
Institute of Interdisciplinary Research in Human and Molecular
Biology, Universtité Libre de Bruxelles. Using P2Y6R−/− bone
marrow derived cells to generate osteoclasts in vitro, Orriss et al.
(2011) demonstrated a reduction in bone resorption compared to
wild-type (WT) osteoclasts. This data complemented their obser-
vation that when UDP, the agonist for the P2Y6 receptor, was
added to mature murine osteoclasts for the ﬁnal 48 h of culture it
signiﬁcantly increased resorption by up to 60%. In the same study
the authors examined the bones of 2-month-old P2Y6R−/− mice
and found that there was a reduction in the number of osteo-
clasts on the surface of the endocortical and trabecular bone.
One would predict that given the observed reduction in osteo-
clast resorptive capacity in vitro and osteoclast numbers in vivo
that the P2Y6R−/− mice would have a high bone mass phenotype.
However, the authors found no signiﬁcant effect of receptor dele-
tion on the amount or architecture of trabecular bone either in the
long bones or vertebrae of the P2Y6R−/− mice, yet they did detect
a signiﬁcant increase in cortical bone volume and thickness. The
reason behind this effect in a discrete bone compartment is not
yet known, and whether the lack of an extreme bone phenotype
is due to purinoceptor redundancy or possible apposing effects of
P2Y6 receptor deletion on osteoblasts remains to be elucidated.
The full publication of further studies using adult P2Y6R−/−
mice under challenged conditions such as mechanical loading
(Gupta et al., 2012) may go some way to explain the enigma of
these mice.
The P2Y13R−/− mouse had a more obvious bone phenotype
that was somewhat unsurprising given the previous reports that
ADP, the preferred agonist of the P2Y13R, is a powerful osteolytic
agent (Hoebertz et al., 2001). In a study recently highlighted by
the Editor of Molecular Endocrinology as “excellent examples of
the relevance of basic science ﬁndings to clinical management of
endocrine disorders” (DeFranco, 2012), Wang et al. (2012) found
that P2Y13R−/− mice had a 40% reduction in trabecular bone
volume, a 50% reduction in both osteoblasts and osteoclasts on the
surface on bone and an overall 50% reduction in bone remodeling
in vivo. This reduced bone turnover maybe as a consequence of
the reduced ratio of the key bone modulating molecules receptor
activator of nuclear factor κ-B ligand and osteoprotegerin and
reduced downstream RhoA/ROCK I signaling. Furthermore, the
reduced bone turnover observed in the P2Y13R−/− mice served to
protect them from ovariectomy-induced bone loss by up to 65%.
These exciting results highlight a potential alternative drug target
for the treatment of bone diseases with accelerated bone turnover
such as estrogen deﬁciency-induced osteoporosis.
Indeed, considerable advances have been made in develop-
ing pharmaceutical modulators of the P2Y receptors. Clopido-
grel (Plavix), a P2Y12 antagonist, was the second most sold
pharmaceutical drug in the world in 2010. The P2Y12 recep-
tor was ﬁrst noted to be expressed by bone cells by Buckley
et al. (2003). Interestingly, recent reports in abstract form have
described an osteopetrotic phenotype of the P2Y12R−/− mice
(Floyd et al., 2008), with delayed osteoclast formation in vitro and
decreased Rap1 phosphorylation in response to ADP stimulation
in P2Y12R−/− cells (Su et al., 2011). These abstracts also suggest a
role for the P2Y12R in pathological bone loss and we eagerly await
the full manuscript.
Another recent development in purinergic signaling using
mouse models has arisen thanks to Jørgensen and colleagues at
the Research Center for Aging and Osteoporosis, Copenhagen
University Hospital who have back-crossed the original Glaxo
P2X7R−/− mouse on to the BALB/cJ strain (Syberg et al., 2010).
The two original P2X7R−/− mousemodels (maintained onmixed
C56BL/6 backgrounds) have a natural P451Lmutation in the cyto-
plasmic domain of the P2X7 receptor which confers drastically
reduced sensitivity to ATP-induced pore formation. While these
existing P2X7R−/− strains have similar and contradictory results
in many tissues including bone (i.e., the ability to form mult-
inucleated osteoclasts in vivo and in vitro and an altered bone
phenotype, respectively) there have been many reports that sup-
port an important role for the P2X7 receptor in bone (Gartland,
2012). Therefore, analysis of this new P2X7R−/− BALB/cJ strain
may offer further new insights into the role of the P2X7R with-
out the possible confounding contribution of the natural P451L
www.frontiersin.org September 2012 | Volume 3 | Article 116 | 3
“fendo-03-00116” — 2013/1/17 — 21:52 — page 4 — #4
Rumney et al. Purinergic signaling in bone
mutation. Initial results have demonstrated that these mice also
maintain the capability to form multinucleated osteoclasts both in
vivo and in vitro (Gartland,2012). In addition,when examining the
ability of different aged mice to form osteoclasts in vitro it appears
that formation and function is enhanced in young and developing
mice, but that in older mice this increased resorptive capacity of
the P2X7R−/− osteoclasts was not as apparent (Agrawal et al.,
2012). Again, we look forward to the full report of the bone
phenotype of this strain and the contribution of this receptor to
osteoclastogenesis.
PURINERGIC SIGNALING AND BONE DISEASE
Exciting progress has also been made in establishing a role for
purinergic signaling in maintenance of healthy bone via studies
involving human patient data. The ﬁrst set of studies involve the
gene for the P2X7 receptor, P2XR7, which is known to be highly
polymorphic with over 26 non-synonymous single nucleotide
polymorphisms (SNPs) listed on the NCBI database (Build 131),
six of which have been previously described as resulting in either
loss or gain of P2X7 receptor function. An initial report from the
lab of Jørgensen reported that two SNPs in the P2X7 receptor gene
(P2XR7)were associatedwith an increased risk of fracture (Ohlen-
dorff et al., 2007). Since then new SNPs have been found and it has
been shown that heterozygote combinations of various SNPs result
in an enhanced effect on the receptor function than any individual
homozygote SNP. Given these observations further analysis of the
role of other P2XR7 SNPs as well as combinations of SNPs in bone
and indicators of osteoporosis, speciﬁcally bone mineral density
(BMD), bone loss, and fracture was clearly warranted.
We have recently published the results of our study using
women from the Aberdeen Prospective Osteoporosis Screening
Study (APOSS) which revealed that a single SNP in the P2XR7,
the c.946A (p.Arg307Gln), was signiﬁcantly associated with low
BMD at the lumbar spine of women aged 45–54 years and at
a follow-up visit between 7 and 9 years later. Further analysis
showed that when women with one or more loss-of-function SNP
were grouped together they had almost a 10-fold increase in the
amount of bone loss per year compared to women who were
WT at these positions (Gartland et al., 2012b). This was the ﬁrst
description that a P2XR7 polymorphism is associated with BMD,
a key determinant of vertebral fracture risk, in post-menopausal
women. The involvement of the P2XR7 in regulating human bone
mass was further highlighted with a complimentary article from
our ATPBone collaborators (Jørgensen et al., 2012a). By geno-
typing women from the Danish Osteoporosis Prevention Study
(DOPS) cohort for the same functional P2XR7 SNPs they con-
ﬁrmed the p.Arg307Gln SNP as being important to bone health –
as women with this SNP had 40% increased bone loss. They also
conﬁrmed the effect of multiple SNPs on bone mass – they found a
clear association between the low-risk (high-P2X7 function) alle-
les and a low rate of bone loss and conversely, high-risk (reduced
P2X7 function) alleles were associated with a high rate of bone
loss. In addition, they found a gain-of-function SNP was asso-
ciated with lower vertebral fracture incidence 10 years after the
menopause. Taken together, these two independent studies pro-
vide strong and compelling evidence that the P2RX7 is involved
in the regulation of bone mass and fracture risk, and may in the
future, represent an early diagnostic tool for the management of
osteoporosis.
In addition to being implicated in osteoporosis, polymor-
phisms in the P2XR7 have been suggested to be involved in
other musculoskeletal complications including aseptic hip loos-
ening and rheumatoid arthritis (RA). A Czech group reported
that the loss-of-function P2RX7 SNPs are overrepresented among
patients with total hip arthroplasty (THA) whilst the p.Arg307Gln
allele was associated with greater cumulative hazard of THA
revision (Mrazek et al., 2010), although the authors acknowl-
edged the limitations of their under-powered study and suggested
that replication is needed. Similarly, a report using a small
cohort from the Omani Arab population is suggestive that poly-
morphism at position c.1068 and c.1513 in the P2X7R gene
might contribute to the pathogenesis of RA as they were over-
represented in the RA group and signiﬁcantly associated with
the presence of rheumatoid factor and anti-MCV autoanti-
body in RA patients, respectively. Whereas neither the loss-of-
function c.1096C > G (p.Thr357Ser) SNP or the gain-of-function
c.489C>T (p.His155Tyr) SNP appeared to be a susceptibility gene
locus for the development of RA (Al-Shukaili et al., 2012). Both
the c.946A (p.Arg307Gln) and c.1729A (p.Ile568Asn) SNPs were
not detected in the Omani Arab population, probably due to low
numbers (MAF 0.01 and 0.03, respectively, in a Caucasian popu-
lation). Again, the authors acknowledged that further clariﬁcation
and replication in a larger cohort was warranted to conﬁrm their
ﬁndings.
Clearly, further replication of the above observations in RA and
aseptic loosening are warranted. As are further analysis of large
cohorts such as DOPS and APOSS for SNPs in other purinergic
receptors such as the P2Y2 receptor, which has a role in bone
homeostasis and is also known to have numerous functional poly-
morphisms associated with other human diseases (Wesselius et al.,
2011), are eagerly anticipated.
As stated earlier, purinergic signaling is the most primitive and
ubiquitous cell-to-cell signaling system that exists, and one might
worry that any drug developed speciﬁcally to target one particu-
lar receptor for one particular disease may have effects in other
systems. The P2Y12 receptor is known to play an important role
in platelet activation – and P2Y12 antagonists have proven thera-
peutic value in the treatment and prevention of coronary artery
disease. As mentioned earlier, the P2Y12 receptor has previously
been identiﬁed as being expressed on human osteoblasts (Buckley
et al., 2003) and an osteopetrotic phenotype of the P2Y12R−/−
mice has been reported (Floyd et al., 2008), although the physio-
logical consequence of P2Y12 receptor activation or inhibition in
human bone is not known.
Taking these previous reports into consideration, Vestergaard
et al. (2011) investigated the use of platelet inhibitors including
clopidogrel. In this study, they found that the inhibitors dipyri-
damole and acetylsalicylic acid were associated with increased
fracture, whereas clopidogrel was not. Even though this was a large
scale study where all patients sustaining a fracture during the year
of 2000 from theDanish populationwere included (approximately
124,655 cases from 5.3 million individuals), the authors postu-
lated that the lack of any association of fracture risk to clopidogrel
was due to the relatively short duration of exposure the patients
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would have had as the drug was only licensed in July 1998. Given
that the number of deﬁned daily doses (DDD) of clopidogrel sold
increased by a factor of 30 from 103,000 in 1999 to 3.4 million in
2003 in Denmark alone additional studies in newer data sets were
clearly warranted. To that end, Jørgensen et al. (2012b) again used
the Danish population to identify patients who were prescribed
clopidogrel during the years 1996–2008 (n = 77,503) and three
non-users, matched for age and gender (n = 232,510), for each
clopidogrel-treated subject to test for an associationbetween clopi-
dogrel use and fracture incidence. Using this data set they found a
biphasic response to clopidogrel use, whereby those patients who
had low exposure to treatment with clopidogrel (<0.01 DDD)
had a lower risk of fracture than non-users, whilst the remaining
patients prescribed clopidogrel had increased overall fracture risk
and increased risk of osteoporotic fractures, especially in subjects
with a treatment duration of more than 1 year.
What is behind these associations has yet to be elucidated. It
could be as a consequence of low-grade inﬂammation associated
with atherosclerosis: inﬂammation is often accompanied by bone
loss and subsequently osteoporosis, thus the inﬂammation related
to cardiovascular disease could be a contributing factor to the bone
loss in the clopidogrel-treated group.
Direct antagonism of P2Y12 receptor expressed by both
osteoblasts and osteoclasts could also be a contributing factor.
Antagonism of the P2Y12 receptor on both cell types would dis-
rupt the balance of bone homeostasis modulating both bone
formation and resorption. This has recently been conﬁrmed by
Syberg et al. (2012) who demonstrated that clopidogrel treat-
ment of osteoblast and osteoclast cultures in vitro resulted in
reduced osteoblast activity and mineralization, an increase in
adipocytes and reduced osteoclast formation, viability, and resorp-
tive activity. One might speculate that the in vitro observations
were due to a non-speciﬁc effect of clopidogrel, which is a pro-
drug that is rapidly metabolized in the liver to form the active
metabolite; whether this occurs in these cultures is undeter-
mined. The authors address this in their manuscript by providing
supporting in vitro evidence for a direct effect in the form of
alterations in cAMP levels and mRNA for key osteoblastic genes
in osteoblasts following clopidogrel treatment. However, they
acknowledge that off target, non-P2Y12 receptor-mediated effects
on osteoblasts in vitro cannot be fully discounted. They then
provide further in vivo evidence that clopidogrel has a detri-
mental effect on bone by comparing the bone parameters of
ovariectomized mice with ovariectomized mice treated daily for
4 weeks with clopidogrel. Clopidogrel-treated mice had exag-
gerated effects of ovariectomy including signiﬁcantly increased
bone resorption and decreased bone formation markers, as well as
enhanced bone loss as evidenced by signiﬁcantly larger reductions
in BMD, trabecular bone volume, and trabecular number. Clearly,
further studies into the exact mechanism of action of clopido-
grel, and the newer and more potent anti-platelet drugs such as
prasugrel and ticagrelor, on bone metabolism are both timely and
necessary.
Finally, the role of purinergic signaling in cancer is gradually
emerging (Deli and Csernoch, 2008), but the role of ATP and
P2 receptors in bone cancer and cancer-induced bone disease
(CIBD) still relatively unexplored. The P2X7 receptor has been
implicated in many cancer types and its antagonism proposed as
a potential treatment (Roger and Pelegrin, 2011). Given its role
in bone cells one would speculate that it would be involved in
bone cancer or CIBD. To date, only one study has investigated
purinergic signaling in bone cancer, speciﬁcally the P2X7 receptor
in bone cancer pain. In this study, Hansen et al. (2011) injected
4T1 cancer cells directly into the femur of the mice and then mea-
sured pain-related behaviors and also bone destruction and tumor
burden. They demonstrated that P2X7R-deﬁcient mice were still
susceptible to bone cancer pain and compared to cancer-bearing
WT mice had an earlier onset of pain-related behaviors. There
was no apparent difference in the bone destruction or tumor
burden between WT and P2X7R-deﬁcient mice, although the
authors note that due to the advanced stage of cancer there was
not a reliable measure of tumor burden in their model. They
suggest that differences between the two genotypes could not
be ruled out and experiments exploring earlier time points to
fully elucidate the role of the P2X7 receptor in bone cancer are
warranted.
SUMMARY
Clearly, we have come a long way in purinergic signaling in bone
since the ﬁrst description almost 20 years ago and we have made
signiﬁcant advances in the past few years thanks to some great
collaboration. The availability of more KO (and transgenic) mod-
els as well as the development and use of speciﬁc antagonists for
other conditions will undoubtedly help us to elucidate further the
exact roles purinergic signaling pathways have to play in bone
homeostasis, both in health and disease.
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